Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 12/20 | 0.70 |
| ▸ | HTR2C | P28335 | 12/20 | 0.70 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998063 | 0.92 | HTR7 (0.62) | HTR7DRD2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL763552 | 0.86 | HTR2A (0.77) | HTR2AHTR2C | |
| SCHEMBL14364784 | 0.85 | HTR2A (0.68) | HTR2AHTR2C | |
| SCHEMBL6088731 | 0.85 | HTR7 (0.78) | HTR7DRD2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL274149 | 0.84 | HTR7 (1.00) | HTR7DRD2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10085949 | 0.84 | HTR7 (0.73) | HTR7DRD2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL30274420 | 0.84 | HTR2A (0.74) | HTR7DRD2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3568230 | 0.84 | HTR7 (1.00) | HTR7DRD2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL7489301 | 0.84 | HTR7 (0.68) | HTR7DRD2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL30274356 | 0.83 | HTR7 (0.70) | HTR7DRD2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850269-A | Tetrahydro-beta-carboline compound and preparation method and application thereof | 南京工业大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | HTR7 2598/4885DRD2 2644/4885CYP3A4 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.